Matt de Gruchy’s Post

A great post by my colleague Matt de Gruchy after Reuters Events Pharma, which had me thinking about the people side of the #GenAI revolution – specifically the #behaviours that need to be fully embedded to deliver on the tech's promise for pharma. Here’s my starter for five: 🧪 Be open to innovation – it’s one of the most innovative industries, so think like pharma. Be open to exploring new approaches and techniques, and try, test and experiment. ❓ Think critically – question and verify AI-generated outputs with rigorous inspection and testing. Use your powerful human judgement to apply GenAI and its outputs in an effective, reliable and ethical way. 🤔 Show curiosity and adaptability – acknowledge that you don’t have all the answers, and be curious about AI-generated insights. Focus on the questions you ask, be receptive to insights, and be adaptable enough to adjust your strategies and hypotheses. ⭕️ Think holistically and iteratively – relevant, specific context is a crucial input to GenAI, but do make space for exploration from all angles. Also allow for multiple iterations of input, refinement and validation to get the best outcome. 🤝 Collaborate – have an enterprise mindset, and maximise the collective expertise of diverse teams to exploit the full potential of GenAI. Work across organisational barriers, sharing data, integrating domain expertise and encouraging collaboration. When I reflect on those, it seems to me that those five behaviours should be well established in pharma organisations. It’s a sector used to driving innovation, to questioning and testing, adapting and iterating, and to working together to enhance outcomes for patients. So the adoption of AI should be plain sailing. Am I right, or is there something about the application of the behaviours to such a transformative technology that might create fresh challenges? Are the behaviours not as embedded as they need to be, or are there other barriers? Let me know what you think! #pharma #culture #innovation

The #AI revolution in #drugdiscovery is more than just a trend — it's a paradigm shift. Traditional methods with lengthy timelines, high costs, and significant failure rates are being replaced by AI’s integration with drug discovery processes. This article explores how AI enhances predictability and efficiency, leveraging data-driven approaches to revolutionize the sector. Read the full article to discover the profound impact AI is having on the industry. https://okt.to/FepWVz #AI #drugdiscovery #pharmaceutical #Logica

At Gradient-BioSciences, we're leveraging AI to revolutionize how new medications are discovered. Here’s a quick look at why this technology is a game-changer in pharmaceutical research: Speed and Efficiency: AI can process and analyze data much faster than traditional methods. This means quicker identification of potential drug candidates, accelerating the path from research to clinical trials. Precision: AI algorithms can predict how different substances will interact at a molecular level with high accuracy. This reduces the likelihood of costly failures in later stages of drug development. Cost Reduction: By enhancing both speed and precision, AI significantly cuts down the overall cost of drug discovery, facilitating more research and innovation within the same budget. We believe AI’s impact on drug discovery not only makes the process more efficient but also more accessible, potentially leading to treatments for diseases faster than ever before. Stay tuned to learn more about how technology is shaping the future of healthcare. #AI #DrugDiscovery #HealthTech #Pharmaceuticals #GradientBioSciences

The pharmaceutical industry has seen a concerted push to harness the power of data for AI, but challenges persist. The future of breakthroughs, such as in drug discovery, lies in collaboration. Breaking down data silos, and facilitating governed, private, and secure computational access to distributed pharma data for ML, will enable a new era of drug discovery. With Apheris, pioneers in the pharmaceutical industry are already collaborating safely on their data to identify new drug candidates, accelerate clinical trials, and develop diagnostic solutions. Robin Röhm on LinkedIn: #pharma #drugdiscovery #ai #ml #datacollaboration #secureai #privateai… https://hubs.li/Q02gf1rX0

Shake up your perspective on the pharmaceutical industry with the latest on its digital evolution! 💊 Fusion of cutting-edge technology and healthcare, propelling us into an era of unprecedented possibilities. Virtual drug trials powered by AI, slashing development timelines and bringing life-saving treatments to market faster than ever before. #pharmaceuticalindustry #digitaltransformation #innovation #ai #machinelearning

Revolutionizing Drug Discovery: How Generative AI is Transforming the Pharmaceutical Industry #generativeai #technology #innovation #pharmaceutical Digital transformation. AI Learn how. AI Discover. Generative AI. Insights in AI. Expert advice. Read our blog. Transform your business with AI. https://lnkd.in/e2ZzJNeN

Revolutionizing Drug Discovery: How Generative AI is Transforming the Pharmaceutical Industry #generativeai #technology #innovation #pharmaceutical Digital transformation. AI Learn how. AI Discover. Generative AI. Insights in AI. Expert advice. Read our blog. Transform your business with AI. https://lnkd.in/e2ZzJNeN

At #BIO2024, there has been fascinating discussion around how AI is transforming R&D and business practices and its value. Locust Walk’s recent "Overview of AI in Biotech" report, underscores AI's profound influence on drug discovery and the pharmaceutical sector over the past five years, with AI-derived assets accounting for almost half of the preclinical pipeline. Moreover, AI-enabled drug firms embrace either near-term revenue-focused strategies or long-term value-driven approaches. Download the report here : https://lnkd.in/egaqv9Z6 Additionally, Locust Walk’s Daniel Brog led an informative panel discussion on “AI Partnerships: Integrating for Strategic Value” at this spring’s Align Summit. Read about the key themes emerging from this panel here: https://lnkd.in/eZhJDeGS  

We are excited to announce our collaboration with OpenAI and Sanofi to build fine-tuned and custom AI solutions to transform drug development. Since our inception, we have focused on building a pharma company differentiated by radical efficiency throughout drug development and clinical trials - and this collaboration helps us advance that vision.    As AI accelerates drug discovery, generating more promising candidate drugs than ever before, we believe the most consequential bottleneck to bringing more medicines to patients is the staggering cost and time needed for drug development and clinical trials. By designing and developing AI specifically tailored for drug development, we can increase the total number of candidate drugs that can progress through development, and ultimately deliver more new treatments to patients faster and more efficiently. You can read more about the collaboration here: https://lnkd.in/eYx9_QYg #ai #drugdevelopment #clinicaltrials #pharma #biotech

AI is revolutionizing drug discovery! Our blog dives into how artificial intelligence is transforming the pharmaceutical landscape. From streamlining complex calculations to predicting protein structures, AI opens up a world of opportunities. Learn about the challenges, the innovative strategies to overcome them, and how Compass can help you navigate this AI-driven future. https://lnkd.in/gxYaDE_B #DrugDiscovery #AIinPharma #BiotechInnovation #FutureOfMedicine #LifeSciencesTrends